Therapeutic drug monitoring of antiretroviral drugs at home using dried blood spots: a proof of concept study

2012 ◽  
Vol 18 (6) ◽  
pp. 821-825 ◽  
Author(s):  
Wiete Kromdijk ◽  
Jan W Mulder ◽  
Patrick M Smit ◽  
Rob ter Heine ◽  
Jos H Beijnen ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Dried Blood Spots ◽  
Antiretroviral Drugs ◽  
Therapeutic Drug ◽  
Proof Of Concept ◽  
Concept Study ◽  
Blood Spots ◽  
At Home

scholarly journals Using dried blood spots to facilitate therapeutic drug monitoring of antiretroviral drugs in resource-poor regions

2018 ◽  
Vol 73 (10) ◽  
pp. 2729-2737 ◽  
Author(s):  
Urs Duthaler ◽  
Benjamin Berger ◽  
Stefan Erb ◽  
Manuel Battegay ◽  
Emili Letang ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Dried Blood Spots ◽  
Antiretroviral Drugs ◽  
Therapeutic Drug ◽  
Blood Spots ◽  
Resource Poor

Therapeutic drug monitoring (TDM) of the recent antipsychotic ziprasidone in dried blood spots (DBS) and plasma

2011 ◽  
Vol 44 (06) ◽  
Author(s):  
L Mercolini ◽  
G Fulgenzi ◽  
M Melis ◽  
G Boncompagni ◽  
LJ Albers ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Dried Blood Spots ◽  
Therapeutic Drug ◽  
Blood Spots

Innovation in microsampling for therapeutic drug monitoring of gentamicin in neonates: a proof-of-concept study

2022 ◽  
pp. 106513
Author(s):  
Suzanne L. Parker ◽  
Adam D. Irwin ◽  
Francine Hosking ◽  
Deanne August ◽  
Brittany Schoenmaker ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Proof Of Concept ◽  
Concept Study

scholarly journals Preanalytical considerations in therapeutic drug monitoring of immunosuppressants with dried blood spots

Diagnosis ◽  
2018 ◽  
Vol 0 (0) ◽  
Author(s):  
Adrian Klak ◽  
Steven Pauwels ◽  
Pieter Vermeersch
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Current Knowledge ◽  
Dried Blood Spots ◽  
Therapeutic Drug ◽  
Drying Time ◽  
Blood Spots ◽  
Home Based ◽  
The Impact ◽  
Blood Spot

Abstract Background Dried blood spots (DBSs) could allow patients to prepare their own samples at home and send them to the laboratory for therapeutic drug monitoring (TDM) of immunosuppressants. The purpose of this review is to provide an overview of the current knowledge about the impact of DBS-related preanalytical factors on TDM of tacrolimus, sirolimus and everolimus. Content Blood spot volume, blood spot inhomogeneity, stability of analytes in DBS and hematocrit (Hct) effects are considered important DBS-related preanalytical factors. In addition, the influence of drying time has recently been identified as a noteworthy preanalytical factor. Tacrolimus is not significantly influenced by these factors. Sirolimus and everolimus are more prone to heat degradation and exhibited variations in recovery which were dependent on Hct and drying time. Summary and outlook DBS-related preanalytical factors can have a significant impact on TDM for immunosuppressants. Tacrolimus is not significantly influenced by the studied preanalytical factors and is a viable candidate for DBS sampling. For sirolimus and everolimus more validation of preanalytical factors is needed. In particular, drying conditions need to be examined further, as current protocols may mask Hct-dependent effects on recovery. Further validation is also necessary for home-based self-sampling of immunosuppressants as the sampling quality is variable.

scholarly journals Comparing Dried Blood Spots and Plasma Concentrations for Busulfan Therapeutic Drug Monitoring in Children

2020 ◽  
Vol 42 (1) ◽  
pp. 111-117 ◽  
Author(s):  
Ana Dilo ◽  
Youssef Daali ◽  
Jules Desmeules ◽  
Yves Chalandon ◽  
Chakradhara R. S. Uppugunduri ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Drug Monitoring ◽  
Plasma Concentrations ◽  
Dried Blood Spots ◽  
Therapeutic Drug ◽  
Blood Spots
Sign in / Sign up

Export Citation Format

Share Document